Effects of fluticasone propionate and beclomethasone dipropionate on parameters of inflammation in peripheral blood of patients with asthma

Bronchial inflammation plays a central role in asthma. We investigated whether parameters of inflammation were increased in peripheral blood. Furthermore, we tested whether fluticasone propionate (FP), a new inhaled corticosteroid (ICS), and beclomethasone dipropionate (BDP) affected these parameter...

Full description

Saved in:
Bibliographic Details
Published in:Allergy (Copenhagen) 1998-07, Vol.53 (7), p.653-661
Main Authors: Bootsma, G. P., Koenderman, L., Dekhuijzen, P. N. R., Festen, J., Lammers, J.‐W. J., Herwaarden, C. L A.
Format: Article
Language:English
Subjects:
activation markers
Administration, Inhalation
Adolescent
Adult
Androstadienes - therapeutic use
Anti-Inflammatory Agents - therapeutic use
asthma
Asthma - blood
Asthma - drug therapy
Asthma - immunology
Beclomethasone - therapeutic use
beclomethasone dipropionate
Biological and medical sciences
CD3 Complex - immunology
Cross-Over Studies
Double-Blind Method
eosinophil cationic protein
Eosinophils - drug effects
Female
Flow Cytometry
Fluticasone
fluticasone propionate
Histamine and antagonists. Allergy
HLA-DR Antigens - immunology
Humans
inflammation
Leukocyte Common Antigens - immunology
Male
Medical sciences
Middle Aged
peripheral blood
Pharmacology. Drug treatments
Phenotype
Receptors, Interleukin-2 - immunology
T-Lymphocytes - immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Bronchial inflammation plays a central role in asthma. We investigated whether parameters of inflammation were increased in peripheral blood. Furthermore, we tested whether fluticasone propionate (FP), a new inhaled corticosteroid (ICS), and beclomethasone dipropionate (BDP) affected these parameters. FP 750 μg/day and BDP 1500 μg/day were compared in a randomized, crossover study consisting of two 6‐week treatment periods, each preceded by a 3‐week placebo period. Twenty‐one patients with symptomatic asthma completed the study. The results were compared with those of six normal subjects (controls). Immunophenotyping of inflammatory cells was performed in whole blood, and serum eosinophil cationic protein (ECP) was measured. With regard to clinical efficacy, ICS increased PCjo histamine by more than 1.9 doubling doses and FEV, by more than 0.34 1. The number of CD3/HLA‐DR+ lymphocytes was significantly increased in asthmatics compared to the normal subjects, both after placebo (P
ISSN:0105-4538
1398-9995
DOI:10.1111/j.1398-9995.1998.tb03951.x